Allianz Asset Management GmbH Has $2.07 Million Stake in Zimmer Biomet Holdings, Inc. $ZBH

Allianz Asset Management GmbH trimmed its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 58.6% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 22,641 shares of the medical equipment provider’s stock after selling 32,013 shares during the period. Allianz Asset Management GmbH’s holdings in Zimmer Biomet were worth $2,065,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. New York State Teachers Retirement System grew its position in Zimmer Biomet by 0.5% in the 2nd quarter. New York State Teachers Retirement System now owns 157,785 shares of the medical equipment provider’s stock worth $14,392,000 after purchasing an additional 851 shares during the last quarter. Generali Asset Management SPA SGR grew its position in Zimmer Biomet by 16.9% in the 2nd quarter. Generali Asset Management SPA SGR now owns 14,110 shares of the medical equipment provider’s stock worth $1,287,000 after purchasing an additional 2,042 shares during the last quarter. Boston Trust Walden Corp grew its position in Zimmer Biomet by 45.0% in the 2nd quarter. Boston Trust Walden Corp now owns 693,322 shares of the medical equipment provider’s stock worth $63,238,000 after purchasing an additional 215,249 shares during the last quarter. Sequoia Financial Advisors LLC lifted its holdings in shares of Zimmer Biomet by 492.4% during the 2nd quarter. Sequoia Financial Advisors LLC now owns 87,885 shares of the medical equipment provider’s stock worth $8,016,000 after acquiring an additional 73,049 shares during the period. Finally, MGO One Seven LLC lifted its holdings in shares of Zimmer Biomet by 59.7% during the 2nd quarter. MGO One Seven LLC now owns 3,717 shares of the medical equipment provider’s stock worth $339,000 after acquiring an additional 1,389 shares during the period. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Zimmer Biomet

In other Zimmer Biomet news, SVP Lori Winkler sold 1,500 shares of the business’s stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $104.15, for a total value of $156,225.00. Following the completion of the transaction, the senior vice president directly owned 6,833 shares of the company’s stock, valued at approximately $711,656.95. The trade was a 18.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 1.39% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on ZBH shares. Rothschild & Co Redburn started coverage on shares of Zimmer Biomet in a report on Thursday, September 18th. They set a “buy” rating and a $130.00 price objective for the company. Roth Capital reaffirmed a “buy” rating on shares of Zimmer Biomet in a report on Thursday, August 7th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Zimmer Biomet in a report on Friday. Evercore ISI reduced their price objective on shares of Zimmer Biomet from $106.00 to $104.00 and set an “in-line” rating for the company in a report on Tuesday, October 7th. Finally, BTIG Research raised their price objective on shares of Zimmer Biomet from $118.00 to $122.00 and gave the stock a “buy” rating in a report on Monday, October 13th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, eight have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $111.94.

Zimmer Biomet Trading Down 0.0%

Shares of ZBH stock opened at $103.14 on Friday. Zimmer Biomet Holdings, Inc. has a 12-month low of $89.22 and a 12-month high of $114.72. The company has a market capitalization of $20.43 billion, a P/E ratio of 25.09, a P/E/G ratio of 2.37 and a beta of 0.67. The firm has a 50-day moving average price of $101.86 and a 200 day moving average price of $97.71. The company has a quick ratio of 0.96, a current ratio of 1.87 and a debt-to-equity ratio of 0.54.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.98 by $0.09. Zimmer Biomet had a net margin of 10.51% and a return on equity of 12.76%. The firm had revenue of $2.08 billion during the quarter, compared to the consensus estimate of $2.06 billion. During the same period last year, the firm posted $2.01 EPS. The firm’s quarterly revenue was up 7.0% on a year-over-year basis. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. Research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be paid a $0.24 dividend. The ex-dividend date of this dividend is Tuesday, September 30th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.9%. Zimmer Biomet’s payout ratio is currently 23.36%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.